Alfred Alberts, Lovastatin Discoverer, Dies

The Merck biochemist found the compound that led to a popular cholesterol-lowering drug.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Alfred Alberts, a biochemist at Merck who discovered a cholesterol-lowering compound that led to the development of a widely used statin, died June 16. He was 87.

“Behind every drug there are heroes,” Michael Brown, a Nobel laureate at the University of Texas Southwestern Medical Center who uncovered key cholesterol-processing steps in cells, tells The New York Times. And Alberts was “an unsung hero.”

Born in 1931 in New York, Alberts studied cell biology, but dropped out of a PhD program at the University of Maryland to take a job at the National Institutes of Health. There, he met his longtime collaborator P. Roy Vagelos in 1959 and began working in his lab. It was the beginning of a life-long partnership.

“He was my right-hand man,” Vagelos tells The Times. “We were more like brothers, like twins.”

In the 1960s, Alberts followed Vagelos to Washington University in St. Louis and, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Accelerating Recombinase Reprogramming with Machine Learning

Accelerating Recombinase Reprogramming with Machine Learning

Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo

Products

waters-logo

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

zymo-research-logo

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-class Research

10x-genomics-logo

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA